Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones Updates

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022

Shaft 301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia

Designation of Two Additional Development Candidates Anticipated in 2022

Organization to Present Pipeline and Business Updates at 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET

CAMBRIDGE, Mass., Jan. 09, 2022 (GLOBE NEWSWIRE) – – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology organization creating accuracy hereditary drugs through base altering, today illustrated expected 2022 achievements across its ex vivo programs focusing on altering of hematopoietic foundational microorganisms (HSCs) and T cells and in vivo programs focusing on altering of liver cells utilizing lipid nanoparticles (LNPs) for conveyance. Refreshes incorporate that the organization has chosen its fourth advancement applicant and first in vivo base altering up-and-comer, BEAM-301, which expects to address the R83C change for the possible treatment of patients with glycogen stockpiling problem Ia (GSDIa).

“We gained critical headway across our base altering portfolio in 2021, which finished in U.S. Food and Drug Administration freedom of the first investigational new medication utilization of a base altering helpful, BEAM-101. We likewise further extended our foundation, especially with LNP conveyance of base editors to the liver and our restrictive innovation for speeding up LNP conveyance to different tissues, including HSCs,” said John Evans, CEO of Beam. “We accept 2022 is set to be our most significant year yet, with arrangements in progress to send off the BEACON-101 clinical preliminary with BEAM-101 for the therapy of sickle cell infection and to finish our change to turning into a clinical-stage organization. We accept we are very much situated today, with four improvement competitors, a rich pipeline of prior stage programs, and an industry-driving foundation of altering and conveyance advancements empowering us to present another class of accuracy hereditary prescriptions. This would be impossible without the responsibility of our amazing group of intrepid trailblazers. We anticipate the year ahead and proceeding with our work to bring conceivably groundbreaking medications to whatever number patients as could reasonably be expected.”

Ex Vivo HSC Programs

Bar 101 is a patient-explicit, autologous HSC investigational treatment, which fuses base alters that are intended to imitate single nucleotide polymorphisms found in people with innate constancy of fetal hemoglobin. Shaft 101 plans to conceivably lighten the impacts of changes causing sickle cell illness (SCD) or beta-thalassemia by prompting expansions in fetal hemoglobin, which hinders hemoglobin S (HbS) polymerization. The BEACON-101 preliminary is a Phase 1/2 clinical preliminary intended to survey the wellbeing and viability of BEAM-101 for the treatment of SCD. The preliminary is relied upon to incorporate an underlying “sentinel” partner of three patients, offered each in turn affirm fruitful engraftment, trailed by dosing in up to an aggregate of 45 patients. Shaft has started site choice and the institutional audit board endorsement processes for the BEACON-101 preliminary and plans to enlist the main subject in the final part of 2022.
Pillar 102 is intended to treat SCD by straightforwardly altering the causative HbS direct change toward reproduce a normally happening ordinary human hemoglobin variation, HbG-Makassar. The Makassar variation has been accounted for to have a similar capacity as the more normal HbA variation and doesn’t cause SCD. Pillar intends to present an investigational new medication (IND) application for BEAM-102 in the last part of 2022.
Ex Vivo T Cell Programs

Shaft 201 is a multiplex base altered enemy of CD7 CAR-T cell investigational treatment intended to treat backslid/hard-headed T cell intense lymphoblastic leukemia, a serious sickness influencing youngsters and grown-ups. Pillar intends to present an IND application for BEAM-201 in the last part of 2022.
Pillar intends to choose a second CAR-T improvement up-and-comer in 2022.
In Vivo LNP Liver-focusing on Programs

Bar 301, the organization’s freshest advancement competitor, is a liver-focusing on LNP definition of base altering reagents intended to address the R83C change. R83C is the most widely recognized illness causing transformation of GSDIa, a life changing hereditary infection with no supported sickness altering therapies accessible today. Pillar expects to start IND-empowering reads up for BEAM-301 out of 2022.
Pillar intends to choose a subsequent liver-designated advancement applicant in 2022.
J.P. Morgan Healthcare Conference
Mr Evans will introduce Beam’s pipeline and business refreshes during a show at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 2:15 p.m. ET. A live webcast will be accessible in the financial backer part of the organization’s site at and will be chronicled for 60 days following the show.

About Beam Therapeutics
Pillar Therapeutics (Nasdaq: BEAM) is a biotechnology organization focused on building up the main, completely incorporated stage for accuracy hereditary drugs. To accomplish this vision, Beam has collected a stage that incorporates a set-up of quality altering and conveyance advancements and is currently assembling inside assembling capacities. Bar’s set-up of quality altering advances is moored by base altering, an exclusive innovation that empowers exact, unsurprising and effective single base changes, at focused on genomic arrangements, without making twofold abandoned breaks in the DNA. This empowers a wide scope of potential helpful altering systems that Beam is utilizing to propel a differentiated arrangement of base altering programs. Pillar is a qualities driven association focused on its kin, state of the art science, and a dream of giving deep rooted fixes to patients experiencing genuine sicknesses.

Preventative Note Regarding Forward-Looking Statements
This public statement holds forward-glimpsing articulations inside the importance of the Private Securities Litigation Reform Act of 1995. Financial backers are forewarned not to put unnecessary dependence on these forward-looking explanations, including, however not restricted to, proclamations connected with: our arrangements, and expected to time, to choose extra improvement up-and-comers, start IND-empowering studies, and submit IND applications; the restorative applications and capability of our innovation, incorporating regarding sickle cell sickness, beta-thalassemia, T-ALL, GSDIa, and LNPs; the arranged inception and plan of our BEACON-101 clinical preliminary, including the circumstance of enlisting the main subject in the preliminary; our arranged introductions at an impending gathering; and our capacity to foster deep rooted, corrective, accuracy hereditary meds for patients through base altering. Each forward-looking assertion is dependent upon significant dangers and vulnerabilities that could make real outcomes vary substantially from those communicated or suggested in such assertion, including, without restriction, dangers and vulnerabilities connected with: our capacity to create, get administrative endorsement for, and popularize our item applicants, which might take longer or cost more than arranged; our capacity to raise extra subsidizing, which may not be accessible; our capacity to get, keep up with and authorize patent and other licensed innovation assurance for our item up-and-comers; the possible effect of the COVID-19 pandemic; that preclinical testing of our item competitors and starter or interval information from preclinical examinations and clinical preliminaries may not be prescient of the outcomes or achievement of continuous or later clinical preliminaries; that enlistment of our clinical preliminaries might take longer than anticipated; that our item up-and-comers might encounter assembling or supply interferences or disappointments; chances connected with serious items; and different dangers and vulnerabilities recognized under the headings “Hazard Factors Summary” and “Hazard Factors” in our Annual Report on Form 10-K for the year finished December 31, 2020, our Quarterly Report on Form 10-Q for the quarter finished March 31, 2021, our Quarterly Report on Form 10-Q for the quarter finished June 30, 2021 and our Quarterly Report on Form 10-Q for the quarter finished September 30, 2021, and in any ensuing filings with the Securities and Exchange Commission. These forward-looking proclamations talk just as of the date of this public statement. Elements or occasions that could make our genuine outcomes contrast might rise up out of an ideal opportunity to time, and it isn’t workable for us to foresee every one of them. We embrace no commitment to refresh any forward-looking assertion, regardless of whether because of new data, future turns of events or in any case, besides as might be needed by material law.


Financial backers:
Chelcie Lister
Push Strategic Communications
[email protected]

Dan Budwick
[email protected]

Leave a Comment

Your email address will not be published. Required fields are marked *